Synthetic binding agents for reducing the fraction of targets that can permeate through mucus and/or freely divide, and methods of reducing mucosal permeation and/or free division of a target using these synthetic binding agents.

Synthetic binding agents for reducing the fraction of targets that can permeate through mucus and/or freely divide, and methods of reducing mucosal permeation and/or free division of a target using these synthetic binding agents.

The invention provides a compound of formula (I): ##STR00001##
or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof, wherein R.sup.1-R.sup.6 have any of the values described in the specification, as well as compositions comprising a compound of formula (I). The compounds are useful as contraceptive agents.

The invention provides a compound of formula (I): ##STR00001##
or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof, wherein R.sup.1-R.sup.6 have any of the values described in the specification, as well as compositions comprising a compound of formula (I). The compounds are useful as contraceptive agents.

The present disclosure relates to inhibitors of mitochondrial function. Methods of screening compounds for mitochondrial inhibition are disclosed. Also described are methods of using mitochondrial inhibitors called mitoriboscins—mitochondrial-based therapeutic compounds having anti-cancer and antibiotic properties—to prevent or treat cancer, bacterial infections, and pathogenic yeast, as well as methods of using mitochondrial inhibitors to provide anti-aging benefits. Specific mitoriboscin compounds and groups of mitoriboscins are also disclosed.

The present disclosure relates to inhibitors of mitochondrial function. Methods of screening compounds for mitochondrial inhibition are disclosed. Also described are methods of using mitochondrial inhibitors called mitoriboscins—mitochondrial-based therapeutic compounds having anti-cancer and antibiotic properties—to prevent or treat cancer, bacterial infections, and pathogenic yeast, as well as methods of using mitochondrial inhibitors to provide anti-aging benefits. Specific mitoriboscin compounds and groups of mitoriboscins are also disclosed.

Modulators of retinoid acid receptor-alpha (RARα) of formula (I) are provided herein, as well as pharmaceutical compositions and methods relating thereto.

##STR00001##

Modulators of retinoid acid receptor-alpha (RARα) of formula (I) are provided herein, as well as pharmaceutical compositions and methods relating thereto.

##STR00001##

The present disclosure relates generally to a method for preventing pregnancy in a female patient and to a method of chemically castrating a male patient.

The present disclosure relates generally to a method for preventing pregnancy in a female patient and to a method of chemically castrating a male patient.